Highly predictive, cost-effective diagnostic assay capable of detecting whether an individual has suffered from an intracerebral hemorrhagic stroke and the likelihood of neurological recovery

Stroke affects 15 million people worldwide each year, and is the number three leading cause of morbidity in the United States. Although most forms of stroke are ischemic in nature, approximately 10-15% of strokes are hemorrhagic. At present, clinical applications for distinguishing between these two forms of stroke do not exist. The present invention describes a highly predictive, cost-effective diagnostic assay capable of detecting whether an individual has suffered from an intracerebral hemorrhagic stroke and the likelihood of neurological recovery. It comprises a rapid screening device for measuring differential expression patterns of nucleic acid molecules or proteins of at least four hemorrhagic stroke-related genes. Accurate prediction of hemorrhagic stroke will improve rapid diagnosis and aid in determining early treatment regimens. Applications: - Gene expression profile assay for determining hemorrhagic stroke victims. - Means of differentiating between hemorrhagic stroke and ischemic stroke thereby optimizing patient response to stroke therapies. Market: - Annually, fifteen billion people suffer from strokes worldwide, and an estimated 700,000 individuals have first-time or recurrent strokes each year in the United States alone. - Almost three-fourth of all strokes occur in individuals over 65 years of age. - In 2006, the projected indirect and direct costs of stroke are $57.9 billion. Development Status: This technology requires clinical validation studies.

U.S. Provisional Application No. 60/807,027 filed 11 Jul 2006 (HHS Reference No. E-197-2006/0-US-01) Inventors: Alison Baird (NINDS) et al.

Licensees sought: Available for non-exclusive or exclusive licensing. Collaborative Research Opportunity: NINDS is also seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this assay for determining hemorrhagic stroke victims. For additional information, please contact: Heather Gunas, J.D., M.P.H; NINDS c/o NCI TTB; 6120 Executive Blvd., Suite 450, Rockville, MD 20852; Phone: 301-451-3944; Fax: 301- 402-2117; Email: gunash@mail.nih.gov.